Owlstone Medical enters into research agreement with Mayo Clinic for study about Pre-Endoscopic Testing for Colonoscopy
Owlstone Medical announce collaboration with Mayo Clinic, the leading US non-profit medical practice, education, and medical research group. Our FAIMS technology is being trialled as a rapid, point-of-care test to non-invasively assess the adequacy of bowel preparation prior to colonoscopy.
Published on: 19 Apr 2017, under Breath Biopsy
Cambridge, UK, April 19, 2017: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced it has entered into a clinical trial agreement with Mayo Clinic. The company’s technology will be used in a clinical trial to evaluate bowel preparation adequacy for patients undergoing colonoscopy.
Colonoscopies are one of the most common gastrointestinal endoscopic procedures with approximately 14 million procedures performed annually in the USA. It is estimated that up to a quarter of these procedures have inadequate bowel preparation, resulting in the need for repeat colonoscopies or increasing the risk that diagnosis of disease, such as colorectal cancer, will be missed.
Mayo Clinic gastroenterologists Liam Zakko, M.D. and Kenneth Wang, M.D. are the principal investigators. Billy Boyle, co-founder and CEO at Owlstone Medical, said: “It is a privilege to be working with one of the leading cancer centers in the US on this important work.”
ENDS
Notes to Editors
Photo: Owlstone Medical’s Lonestar VOC Analyzer
For a high resolution image please contact sarah.jeffery@zymecommunications.com
Media contact
For more information please contact:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730 919
About Owlstone Medical
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs by 2020.
The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.
Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.
Founded in 2004 as a spin-out from the Engineering Department at the University of Cambridge, Owlstone Inc is a profitable business selling its proven FAIMS technology to military and industrial customers globally. Owlstone Medical was spun out from Owlstone Inc in 2016 to develop and commercialise FAIMS in diagnostic applications.
Owlstone Medical is headquartered in Cambridge, UK, with offices in London, UK.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information visit http://www.mayoclinic.org/about-mayo-clinic or http://newsnetwork.mayoclinic.org/ .
